Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Verapamil Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Lannett Company, Inc.
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under terms of the amendment, Societal will now receive improved overall economics, including a 10% increase in the profit share component of revenue from Verapamil PM product sales, as well as immediate and scheduled increases in manufacturing prices.
Brand Name : Verelan PM
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 12, 2022
Lead Product(s) : Verapamil Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Lannett Company, Inc.
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?